Centric Wealth Management’s MAIA Biotechnology MAIA Stock Holding History

Centric Wealth Management’s Portfolio MAIA Stock Details MAIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.11M	Buy	796,723 +210,325	+36%	+$388K	0.22%	88
2025 Q4	$1.14M	Buy	586,398 +11,500	+2%	+$15K	0.24%	86
2025 Q3	$713K	Buy	574,898 +1,500	+0.3%	+$2.45K	0.16%	104
2025 Q2	$872K	Buy	573,398 +505,150	+740%	+$904K	0.21%	95
2025 Q1	$104K	Buy	68,248 +29	+0%	+$54	0.03%	172
2024 Q4	$135K	Hold	68,219	–	–	0.04%	160
2024 Q3	$217K	Buy	68,219 +21	+0%	+$65	0.06%	162
2024 Q2	$226K	Buy	68,198 +1,000	+1%	+$3.15K	0.07%	152
2024 Q1	$197K	Hold	67,198	–	–	0.06%	155
2023 Q4	$96.8K	Buy	67,198 +2,542	+4%	+$4.1K	0.03%	153
2023 Q3	$142K	Buy	64,656 +200	+0.3%	+$396	0.06%	118
2023 Q2	$142K	Buy	64,456 +24,250	+60%	+$64.9K	0.06%	115
2023 Q1	$139K	Hold	40,206	–	–	0.06%	102
2022 Q4	$141K	Buy	+40,206	New	+$139K	0.07%	99

Other funds holding MAIA

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Centric Wealth Management's MAIA Position: Q1 2026 in Review

Centric Wealth Management increased its MAIA Biotechnology (MAIA) stake by 36% in Q1 2026, buying an estimated $388K and bringing the position to 796,723 shares worth $1.11M. The position accounts for 0.22% of the portfolio, ranked #88.

Centric Wealth Management first reported a position in MAIA in Q4 2022 and has held it in 14 quarters since. The position peaked at $1.14M in Q4 2025. 33 funds tracked by Wall St. Rank hold MAIA as of Q1 2026.

Centric Wealth Management held 796,723 shares of MAIA Biotechnology worth $1.11M as of Q1 2026.
Centric Wealth Management bought 210,325 MAIA Biotechnology shares in Q1 2026, an estimated $388K.
MAIA Biotechnology made up 0.22% of Centric Wealth Management's portfolio in Q1 2026, its #88 holding.
Centric Wealth Management first reported a position in MAIA Biotechnology in Q4 2022 and has held it in 14 quarters since.
Centric Wealth Management's MAIA Biotechnology position peaked at $1.14M in Q4 2025.
33 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q1 2026.

Based on Centric Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.